Jump Into an All-New Mickey & Friends Adventure with Disney Illusion Island on July 28
9.2.2023 17:00:00 EET | Business Wire | Press release
Embark on a brand-new adventure with Disney Mickey Mouse’s triumphant return to video games – and this time he’s bringing a few friends! Today, Disney, in collaboration with developer Dlala Studios, revealed that Disney Illusion Island , an upcoming local cooperative 2D platform adventure video game for up to four players, will debut exclusively for Nintendo Switch™ on July 28, 2023. Additionally, pre-orders for Disney Illusion Island are available for $39.99 in Nintendo eShop and at retail, beginning today.
“Fans are in for a treat with the upcoming launch of the whimsical cartoon-like experience offered by Disney Illusion Island,” said Luigi Priore, VP, Disney, Pixar and 20th Century Games. “We’re thrilled to work with developer Dlala Studios as they expand upon the Mickey & Friends world with a new and original storyline, engaging gameplay and delightful hand-drawn art style.”
Join Mickey Mouse, Minnie Mouse, Donald Duck and Goofy and set off on a perilous quest to explore the colorfully hand-crafted and yet mysterious island of Monoth in an escapade to recover three magical Tomes – powerful books used to protect the island. Featuring the voice actors of Mickey, Minnie, Donald, and Goofy and an original orchestral score, players can immerse themselves in a solo adventure or team up with up to three friends in local co-op to use special team skills such as Rope Drop, Leap Frog, and a heart gifting Hug to save the island. Discover rich biomes and never-before-seen environments, meet strange yet intriguing characters, and uncover hidden secrets galore!
But the journey will not be easy, and with intrigue afoot, not everything is what it seems on “Illusion Island.”
“Words cannot express how excited we are for players to embrace the Dlala-spin on this brand-new experience for Mickey Mouse, Minnie Mouse, Donald Duck and Goofy,” said AJ Grand-Scrutton, Lead Developer, Dlala Studios. “It has been an incredible honor working on this title and we hope that Nintendo Switch players and Disney fans worldwide love playing it as much as we've loved creating it.”
Disney Illusion Island will be available for $39.99 and will debut worldwide exclusively for Nintendo Switch on July 28, 2023.
For more information about Disney Illusion Island: https://games.disney.com/disney-illusion-island
To watch the latest trailer: https://www.youtube.com/watch?v=Ll9zSkf4Cfw
For Disney Illusion Island assets: https://drive.google.com/drive/folders/1sVurQkkRn_Tq94FDsbBipvWoP3-ssuhe?usp=sharing
For more updates on Disney Illusion Island, please follow us on social below:
About Dlala Studios
Dlala Studios are the creators of Battletoads (2020), and have previously worked on award-winning titles such as Sea of Thieves, The Escapists, and Lost Words: Beyond The Page. The Essex-based studio celebrated their 10th anniversary in 2022, and are currently developing Disney Illusion Island for the Nintendo Switch.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005020/en/
Contact information
MEDIA CONTACT
Disney Consumer Products, Games and Publishing
Dashaun Gasque
Communications Manager
DASHAUN.GASQUE@DISNEY.COM
Dylan Quintero
Senior Specialist, Communications
DYLAN.QUINTERO@DISNEY.COM
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom